Fermentation process of human serum albumin
By optimizing the whole sequence of the gene of human serum albumin and using the expression system of CBS7435 host bacteria, combined with fermentation process and reactor control, the problems of low gene expression level and immature purification process are solved, and high efficiency and high purity are achieved Human serum albumin preparation.
Patent Information
- Application Number
- CN202411108314.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-12-06
AI Technical Summary
The existing preparation of genetic recombinant human serum albumin has low gene expression levels, immature control of fermentation process, and immature purification process of recombinant human serum albumin, resulting in low expression levels, high purity requirements but low purification efficiency and recovery rate. .
The full sequence optimization design of the target gene at the molecular level is combined with the latest international Pichia expression system host bacteria CBS7435, using the G418 resistance gene to screen high copy number transformants, and optimize the expression level through fermentation and culture process and reactor process control. , and pretreatment such as solid-liquid separation, heat treatment and ultrafiltration concentration of fermentation liquid, combined with three-step column chromatography to achieve high purity recombinant human serum albumin purification.
High-level expression and high purity of recombinant human serum albumin (up to more than 99%) were achieved, and the efficiency and recovery of the purification process were improved.
Smart Images

Figure CN119080914A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the biotechnology field of preparing human serum albumin by utilizing genetic engineering technology, and specifically is a fermentation process of human serum albumin. Background Art
[0002] The development of molecular biology technology has provided many methods and means for producing foreign proteins using bioreactors. So far, a variety of foreign protein expression systems have been developed, such as Escherichia coli, yeast, insects, and mammalian cells. After nearly three decades of development, the Pichia pastoris gene expression system has become one of the most important hosts for expressing foreign proteins, such as the host bacteria GS115 (Cregg, et al (2009). Methods Enzymol. 463, 169-189; US Patent 4, 879, 231, Phillips Petroleum, 1989). This system has the characteristics of easy high-density fermentation, stable integration of the target gene in the host genome, effective secretion and moderate glycosylation of the expression product, and low-cost and economical culture medium. This gene expression system utilizes the highly efficient and regulatable promoter AOX1, and has efficiently expressed thousands of exogenous proteins such as HBsAg, TNF, EGF, tetanus toxin C fragment, genetically engineered antibodies, etc., proving that the system is efficient, practical, simple, and has the outstanding characteristics of increasing expression levels while maintaining the biological activity of the product. It is also very suitable for pilot-scale expansion and expansion to industrial-scale production.
[0003] The expression of foreign genes using Pichia pastoris generally includes the following steps: ① inserting foreign genes into Pichia pastoris recombinant expression vectors; ② treating linearized recombinant plasmids with endonucleases and then transforming Pichia pastoris strains; ③ coating the transformation solution on MD plates for the first round of screening of positive recombinants; ④ using YPD plates containing different concentration gradients of G418 for the second round of screening of positive recombinants; ⑤ further identifying the integration of foreign genes in the yeast genome; ⑥ identifying the expression level of foreign genes by small-scale induced expression; ⑦ using bioreactors for large-scale fermentation production and preparing recombinant proteins from the fermentation broth. In order to increase the expression of foreign genes in Pichia pastoris, it is usually necessary to screen Pichia pastoris transformants containing high-copy number foreign genes, that is, to increase the gene dosage in the host bacteria; and the screening of high-copy number transformants is completed by gradually increasing G418 resistance, which is a very complicated and random task in itself; further investigation shows that there are still many variables between high-copy Pichia pastoris transformants and high-expression foreign proteins, because different target genes present different optimal copy numbers, and there is no linear relationship between the two. The G418 resistance gene is introduced into the commonly used series of recombinant expression vectors pIC9K, pIC3.5K, etc. in Pichia pastoris. After transforming the host bacteria, the exogenous gene and the resistance gene are simultaneously integrated into the chromosome of Pichia pastoris by homologous recombination. By improving the G418 resistance screening, transformants containing the target gene with a small probability of multiple copies inserted in the transformant population can be screened.
[0004] In order to screen positive clones with high copy numbers, it is necessary to use G418 plates with different concentration gradients for screening. The G418 concentration gradient of the preliminary experiment is set to 0, 0.25, 0.5, 0.75, 1.0, 1.5, 1.75, 2.0, 3.0, 4.0 mg / ml. The screening scheme is introduced in the protocol recommended by Invitrogen. The first method is to prepare G418 plates with different concentration gradients, and use the photocopy method to photocopy the positive clones on the HIS4 nutritional deficiency plate one by one onto the G418 gradient plate for screening of high copy number clones. The characteristics of this method are huge workload (it is necessary to transfer and culture three times continuously before photocopying to ensure that the concentration of each single transformant is equivalent during photocopying), high screening difficulty, long cycle, and relatively small number of transformants screened, and high-throughput screening cannot be performed. The second method also needs to prepare G418 plates with different concentration gradients. The difference is that all positive transformants grown on the HIS4 nutrient deficiency plate can be washed with sterile water or liquid culture medium, and then diluted to a suitable concentration, and a certain amount of dilution liquid is applied to the plates containing G418 with different concentration gradients. The operation of this method is relatively simple, and more transformants can be screened. However, for containing different target genes or different Pichia host bacteria, it is necessary to do pre-experiments in advance to explore the dilution of bacterial solution. These two screening schemes are the general screening methods used by scientific and technological workers at home and abroad when expressing exogenous proteins using Pichia expression systems. However, their common disadvantages are that the amount of G418 is large, the operation is cumbersome, the workload is large, time-consuming and labor-intensive, and the versatility of the screening methods of different Pichia host bacteria is poor. Summary of the invention
[0005] 1. Technical problem to be solved by the invention
[0006] The purpose of the present invention is to solve the problems of low gene expression level, immature fermentation process control technology (due to the large fermentation scale, large fermentation tanks of ten tons or dozens of tons are often required, and there are no precedents and tools for process control and detection of large tanks), and immature purification technology of recombinant human serum albumin (due to recombinant human serum albumin is a special case, the purification scale and equipment of the target protein are particularly large-scale, and the purity requirement of the target protein is particularly high, reaching 99.99% or more), that is, there are more than a dozen purification steps, low purification medium loading capacity, low purification efficiency and low purification recovery rate.
[0007] 2. Technical solution
[0008] In order to achieve the above object, the technical solution provided by the present invention is:
[0009] A fermentation process for human serum albumin of the present invention comprises the following steps:
[0010] S210, preparing culture medium;
[0011] S220, electrode calibration;
[0012] S230, feeding;
[0013] S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin;
[0014] S250, fermentation;
[0015] S260, place the can.
[0016] Preferably, the novel host bacteria that highly expresses human serum albumin in step S240 is Pichia pastoris HSA-C16, which is deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with a deposit number of CGMCC No. 30175 and a deposit date of March 28, 2024.
[0017] Preferably, the culture medium of step S210 includes the following components: H3PO4, CaSO4·2H2O, K2SO4, MgSO4·7H2O, KOH, biotin, ammonia water, 98% glycerol or 100% methanol, and a defoaming agent.
[0018] Preferably, the content of H3PO4 is 26.7 ml / L, the content of CaSO4·2H2O is 0.47 g / L, the content of K2SO4 is 9.1 g / L, the content of MgSO4·7H2O is 7.5 g / L, the content of KOH is 4.13 g / L, the content of 98% glycerol is 40 g / L, the concentration of methanol in the fermentation liquid in the tank is controlled at 0.2-0.9%, and the content of the defoaming agent is 0.5 ml / L.
[0019] Preferably, the electrode calibration in step S200 is specifically to calibrate the pH electrode and the dissolved oxygen electrode of the fermentation tank.
[0020] Preferably, the step S230 of feeding is specifically to feed the culture medium mixture prepared in step S210, and then extinguish the fire at high temperature and cool it for standby use.
[0021] Preferably, the novel host bacteria that highly expresses human serum albumin is an engineered bacterium that expresses genetic recombinant HSA obtained by introducing a recombinant expression vector into Pichia pastoris CBS7435 strain, and the nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO: 1.
[0022] Preferably, the recombinant expression vector comprises:
[0023] (1) A 5' regulatory region derived from Pichia pastoris, comprising a promoter element, wherein the 5' regulatory region is selected from the alcohol oxidase AOX1 gene, the dihydroxyacetone synthase DAS1 gene or the histidinol dehydrogenase HIS4 gene derived from Pichia pastoris, and the 3' end of the regulatory region is connected to the sequence of (2) below;
[0024] (2) An optimized gene encoding human serum albumin, wherein the nucleotide sequence contained therein is as shown in SEQ ID NO:2, and the amino acid sequence contained therein is as shown in SEQ ID NO:3;
[0025] (3) A 3' terminator sequence derived from methanolic yeast, wherein the 3' terminator sequence is selected from the 3' terminator sequence of AOX1 gene, AOX2 gene or His4 gene derived from Pichia pastoris.
[0026] Preferably, it also includes
[0027] At least one marker gene that can be selected in E. coli;
[0028] A DNA fragment with a replication origin capable of replicating in an E. coli host bacterium;
[0029] The invention also comprises at least two marker genes which can be selected in yeast.
[0030] Preferably, the recombinant expression vector is a linearized vector of any one of pPIC9, pPIC3, pPICZαABC, pPIC3.5K, pHIL-S1, pHIL-D2, pA0804, pA0815, pGAPZαABC, pPIC6αABC, and pPIC9K after being digested with restriction endonuclease SacI or BglⅡ.
[0031] Preferably, the recombinant expression vector is a linearized vector obtained by digesting HSA-pPIC9K with restriction endonuclease SacI or BglⅡ, and contains at least one copy of an optimized gene encoding human serum albumin.
[0032] Preferably, in the optimized gene encoding human serum albumin, preferred codons of the Pichia pastoris alcohol oxidase (AOX1) gene are selected and the preferred codons of the gene are controlled to account for 90% of the total number of codons encoded by the optimized gene.
[0033] Preferably, in the optimized gene encoding human serum albumin, three restriction endonuclease sites, namely SalI, Hind III and Xba I, are sequentially inserted from 5' to 3' inside the optimized gene, so that the optimized gene is relatively evenly divided into four large fragments.
[0034] Preferably, in the optimized gene encoding human serum albumin, continuous GC pairing is reduced, and AT pairing preferred by Pichia pastoris is increased, so that the GC content within the optimized gene is adjusted to 45-50%.
[0035] Preferably, the optimized gene encoding human serum albumin also includes an expression reading frame of
[0036] The restriction endonuclease BamHI site at the 5' end was inserted into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxyoligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e. AXXATG), and then the yeast a-mating child leader peptide (consisting of 85 amino acids) sequence from Saccharomyces cerevisiae, and then the HSA mature gene was inserted between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector;
[0037] The coding sequence AAAAGA of two dibasic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene, and the specific sequence is SEQ ID NO: 4; the double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene, and the specific sequence is SEQ ID NO: 5.
[0038] Preferably, the fermentation in step S250 includes a basic culture stage, a transition culture stage and an induced expression stage.
[0039] Preferably, the basic culture stage is specifically
[0040] At the beginning of the fermentation of engineered bacteria, the SCADA process control software was started to record data, fermentation time and batch number, and the map record was turned on; from the time the inoculated bacteria were put into the fermentation tank, the relevant fermentation data were recorded regularly every 4 hours; the control parameters were set as follows: pH was controlled at 5.5±0.1 with ammonia water, and the temperature was controlled at 28±1℃; DO value was controlled above 30, air flow was 2vvm, and tank pressure was controlled at 0.03~0.04Mpa; after DO rebounded, it entered the transition culture phase; sampling was taken to detect OD during the rebound 600 It should be around 50.
[0041] Preferably, the transitional culture stage is specifically
[0042] After DO rebounds during the transitional culture stage, 50% glycerol is immediately fed, and 12 ml / L of PTM1 solution containing biotin is added to the 50% glycerol. At the same time, the stirring is adjusted to the maximum speed specified by the fermenter, the air flow is adjusted to 2vvm, and the tank pressure is adjusted to 0.04-0.08Mpa. Under this condition, the feeding rate controls the DO value at 30±10; DO-Spike is performed at least once every hour to ensure that the DO-Spike response time is less than 60 seconds; the feeding cycle is about 4-5 hours; when glycerol is fed, the pH setting value is adjusted on average every hour so that the pH is the induced pH value of 5.7 required by the project after the glycerol feeding is completed; at the end of the transitional culture, OD 600 ≈100.
[0043] Preferably, the induction expression stage is specifically
[0044] After the addition of glycerol stops, after the dissolved oxygen DO rebound is observed, 4g / L of methanol is added and 12ml / L of PTM1 is added to the methanol; after the methanol to be added is consumed (DO rebound), methanol is started to be added in a DO-Spike manner, and the DO-Spike response time is less than 60 seconds, and the DO value is controlled at 10-30; at the same time as the methanol is started, the temperature is adjusted to 24°C; the pH is controlled at the project specified pH 5.7; and DO-Spike is performed every 12 hours, and the response time and other fermentation data are recorded; sampling is performed every 12 hours, the pH and the wet weight of the engineered bacteria are tested, centrifuged, 100μl of the supernatant is added to the electrophoresis buffer, boiled at 100°C for 5 minutes, and stored at -20°C; the remaining supernatant is stored in a refrigerator at 2-8°C for detection or electrophoresis analysis; the samples are marked when sampling; during the induction expression stage, the methanol concentration in the fermentation liquid in the tank is maintained between 0.2-0.9%.
[0045] 3. Beneficial effects
[0046] Compared with the prior art, the technical solution provided by the present invention has the following beneficial effects:
[0047] The fermentation process of human serum albumin of the present invention comprises the following steps: S210, preparing culture medium; S220, calibrating electrodes; S230, feeding; S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin; S250, fermentation; S260, releasing the tank. The target gene with the most suitable expression of Pichia pastoris is obtained by adopting the optimization design of the full sequence of the target gene at the molecular level; the latest Pichia pastoris expression system host bacterium CBS7435 is introduced internationally for the gene expression of human serum albumin; the G418 resistance gene is used to screen Pichia pastoris transformants containing high-copy number exogenous genes, and is used to construct Pichia pastoris engineering bacteria that express high-level recombinant human serum albumin; the expression level of the target protein is further improved by exploring the optimization scheme of the fermentation culture process and the reactor process control, so as to obtain recombinant human serum albumin with a purity of more than 99%.
[0048] Biological Deposit Description Pichia pastoris HSA-C16 was deposited in the General Microbiology Center of China Microorganism Culture Collection (CGMCC) on March 28, 2024. The deposit address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 30175. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 A schematic diagram of a computer-simulated alignment curve in which the GC pairing content within the nucleotide sequence of the optimized gene as shown in SEQ ID NO: 2 of the embodiment is adjusted to an optimal ratio;
[0050] Figure 2 This is a map of the Pichia multi-copy recombinant expression vector pPIC9K of the embodiment;
[0051] Figure 3 Agarose gel electrophoresis (1% agarose gel) of the optimized gene of the embodiment;
[0052] Figure 4 Schematic diagram of the construction process of the recombinant plasmid of the embodiment;
[0053] Figure 5 Optimized gene nucleotide sequence analysis map 1 of the embodiment;
[0054] Figure 6 The optimized gene nucleotide sequence analysis map 2 of the embodiment;
[0055] Figure 7 The optimized gene nucleotide sequence analysis map 3 of the embodiment;
[0056] Figure 8This is a schematic diagram of the cell state changes of the recombinant plasmid into the Pichia pastoris host bacteria by electrotransformation in the embodiment;
[0057] Fig. 9 This is a schematic diagram of the cell state changes of the host bacteria Pichia pastoris GS115 after the recombinant plasmid is transformed into the host bacteria Pichia pastoris GS115 by electroporation in the embodiment;
[0058] Fig.10 This is a schematic diagram of the cell state changes of the host bacteria Pichia pastoris CBS7435 after the recombinant plasmid is transformed into the host bacteria Pichia pastoris CBS7435 by electroporation in the embodiment;
[0059] Fig.11 Results of the pilot induction experiment of the Pichia pastoris GS115 engineered strain prepared in the example Figure 1 ;
[0060] Fig.12 Results of the pilot induction experiment of the Pichia pastoris GS115 engineered strain prepared in the example Figure 2 ;
[0061] Fig.13 Results of the pilot induction experiment of the Pichia pastoris CBS7435 engineered strain prepared in the example Figure 1 ;
[0062] Fig.14 Results of the pilot induction experiment of the Pichia pastoris CBS7435 engineered strain prepared in the example Figure 2 ;
[0063] Fig.15 Schematic diagram of protein electrophoresis of the engineered strain prepared in the example at different time points in the 50L fermenter fermentation test Figure 1 ;
[0064] Fig.16 Schematic diagram of protein electrophoresis of the engineered strain prepared in the example at different time points in the 50L fermenter fermentation test Figure 2 ;
[0065] Fig.17 Schematic diagram of protein electrophoresis of the engineered strain prepared in the example at different time points in the 50L fermenter fermentation test Figure 3 ;
[0066] Fig.18 The standard curve for quantitative determination of protein concentration measured by bovine serum albumin as a standard in the embodiment;
[0067] Fig.19 Schematic diagram of the separation and purification results of the supernatant sample of the engineered strain prepared in the example in a 50L fermenter Figure 1 ;
[0068] Fig. 20This is a purity identification data diagram of the serum albumin sample purified in Example;
[0069] Fig.21 This is a schematic diagram of the non-reduced molecular weight TIC spectrum analysis comparison of the serum albumin sample purified in the example and the rHSA national standard;
[0070] Fig. 22 Schematic diagram of TIC analysis of reduced molecular weight of serum albumin sample purified in Example and rHSA national standard;
[0071] Fig.23 Schematic diagram of the comparison of the reduced molecular weight mass spectrometry analysis of the serum albumin sample purified in the example and the rHSA national standard. DETAILED DESCRIPTION
[0072] In order to enable those skilled in the art to better understand the solution of the present application, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present application.
[0073] It should be noted that the terms "first", "second", etc. in the specification and claims of the present application and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequential order. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present application described here. In addition, the terms "including" and "having" and any of their variations are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device comprising a series of steps or units is not necessarily limited to those steps or units clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.
[0074] In the present application, the terms "upper", "lower", "left", "right", "front", "back", "top", "bottom", "inner", "outer", "middle", "vertical", "horizontal", "lateral", "longitudinal" and the like indicate positions or positional relationships based on the positions or positional relationships shown in the drawings. These terms are mainly used to better describe the present application and its embodiments, and are not used to limit the indicated devices, elements or components to have a specific orientation, or to be constructed and operated in a specific orientation.
[0075] In addition, some of the above terms may be used to express other meanings in addition to indicating orientation or positional relationship. For example, the term "on" may also be used to express a certain dependency or connection relationship in some cases. For those of ordinary skill in the art, the specific meanings of these terms in this application can be understood according to specific circumstances.
[0076] In addition, the terms "installed", "set", "provided with", "connected", "connected", and "socketed" should be understood in a broad sense. For example, it can be a fixed connection, a detachable connection, or an integral structure; it can be a mechanical connection or an electrical connection; it can be a direct connection, or an indirect connection through an intermediate medium, or it can be an internal connection between two devices, elements, or components. For those of ordinary skill in the art, the specific meanings of the above terms in this application can be understood according to specific circumstances.
[0077] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present application will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.
[0078] Example 1
[0079] A fermentation process for human serum albumin of the present invention comprises the following steps:
[0080] S210, preparing culture medium;
[0081] S220, electrode calibration;
[0082] S230, feeding;
[0083] S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin;
[0084] S250, fermentation;
[0085] S260, place the can.
[0086] The novel host bacteria for highly expressing human serum albumin in step S240 is Pichia pastoris HSA-C16, which is deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with a deposit number of CGMCC No. 30175 and a deposit date of March 28, 2024.
[0087] The culture medium of step S210 includes the following components: H3PO4, CaSO4·2H2O, K2SO4, MgSO4·7H2O, KOH, biotin, ammonia water, 98% glycerol or 100% methanol, and a defoaming agent.
[0088] The content of H3PO4 is 26.7 ml / L, the content of CaSO4·2H2O is 0.47 g / L, the content of K2SO4 is 9.1 g / L, the content of MgSO4·7H2O is 7.5 g / L, the content of KOH is 4.13 g / L, the content of 98% glycerol is 40 g / L, the concentration of methanol in the fermentation liquid in the tank is controlled at 0.2-0.9%, and the content of defoaming agent is 0.5 ml / L.
[0089] The electrode calibration in step S200 specifically includes calibrating the pH electrode and the dissolved oxygen electrode of the fermentation tank.
[0090] The step S230 of feeding specifically includes feeding the culture medium mixture prepared in step S210, and then extinguishing the fire at high temperature and cooling it for standby use.
[0091] The novel host bacteria for highly expressing human serum albumin is an engineered bacterium for expressing gene recombinant HSA obtained by introducing a recombinant expression vector into Pichia pastoris CBS7435 strain. The nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO:1.
[0092] The recombinant expression vector comprises:
[0093] (1) A 5' regulatory region derived from Pichia pastoris, comprising a promoter element, wherein the 5' regulatory region is selected from the alcohol oxidase AOX1 gene, the dihydroxyacetone synthase DAS1 gene or the histidinol dehydrogenase HIS4 gene derived from Pichia pastoris, and the 3' end of the regulatory region is connected to the sequence of (2) below;
[0094] (2) An optimized gene encoding human serum albumin, wherein the nucleotide sequence contained therein is as shown in SEQ ID NO:2, and the amino acid sequence contained therein is as shown in SEQ ID NO:3;
[0095] (3) A 3' terminator sequence derived from methanolic yeast, wherein the 3' terminator sequence is selected from the 3' terminator sequence of AOX1 gene, AOX2 gene or His4 gene derived from Pichia pastoris.
[0096] Also includes
[0097] At least one marker gene that can be selected in E. coli;
[0098] A DNA fragment with a replication origin capable of replicating in an E. coli host bacterium;
[0099] The invention also comprises at least two marker genes which can be selected in yeast.
[0100] Preferably, the recombinant expression vector is a linearized vector of any one of pPIC9, pPIC3, pPICZαABC, pPIC3.5K, pHIL-S1, pHIL-D2, pA0804, pA0815, pGAPZαABC, pPIC6αABC, and pPIC9K after being digested with restriction endonuclease SacI or BglⅡ.
[0101] The recombinant expression vector is a linearized vector obtained by digesting HSA-pPIC9K with restriction endonuclease SacI or BglII, and contains at least one copy of an optimized gene encoding human serum albumin that is optimally designed.
[0102] In the optimized gene encoding human serum albumin, the preferred codons of the alcohol oxidase (AOX1) gene of Pichia pastoris are selected and the preferred codons of the gene are controlled to account for 90% of the total number of codons of the optimized gene.
[0103] In the optimized gene encoding human serum albumin, three restriction endonuclease sites, namely SalI, Hind III and Xba I, are sequentially inserted from 5' to 3' inside the optimized gene, so that the optimized gene is relatively evenly divided into four large fragments.
[0104] In the optimized gene encoding human serum albumin, continuous GC pairing is reduced, and AT pairing preferred by Pichia pastoris is increased, so that the GC content inside the optimized gene is adjusted to 45-50%.
[0105] The optimized gene encoding human serum albumin also includes an expression reading frame of
[0106] The restriction endonuclease BamHI site at the 5' end was inserted into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxyoligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e. AXXATG), and then the yeast a-mating child leader peptide (consisting of 85 amino acids) sequence from Saccharomyces cerevisiae, and then the HSA mature gene was inserted between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector;
[0107] The coding sequence AAAAGA of two dibasic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene, and the specific sequence is SEQ ID NO: 4; the double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene, and the specific sequence is SEQ ID NO: 5.
[0108] The fermentation in step S250 includes a basic culture stage, a transition culture stage and an induced expression stage.
[0109] The basic training stage is specifically:
[0110] At the beginning of the fermentation of engineered bacteria, the SCADA process control software was started to record data, fermentation time and batch number, and the map record was turned on; from the time the inoculated bacteria were put into the fermentation tank, the relevant fermentation data were recorded regularly every 4 hours; the control parameters were set as follows: pH was controlled at 5.5±0.1 with ammonia water, and the temperature was controlled at 28±1℃; DO value was controlled above 30, air flow was 2vvm, and tank pressure was controlled at 0.03~0.04Mpa; after DO rebounded, it entered the transition culture phase; sampling was taken to detect OD during the rebound 600 It should be around 50.
[0111] The transitional culture stage is specifically
[0112] After DO rebounds during the transitional culture stage, 50% glycerol is immediately fed, and 12 ml / L of PTM1 solution containing biotin is added to the 50% glycerol. At the same time, the stirring is adjusted to the maximum speed specified by the fermenter, the air flow is adjusted to 2vvm, and the tank pressure is adjusted to 0.04-0.08Mpa. Under this condition, the feeding rate controls the DO value at 30±10; DO-Spike is performed at least once every hour to ensure that the DO-Spike response time is less than 60 seconds; the feeding cycle is about 4-5 hours; when glycerol is fed, the pH setting value is adjusted on average every hour so that the pH is the induced pH value of 5.7 required by the project after the glycerol feeding is completed; at the end of the transitional culture, OD 600 ≈100.
[0113] The induction expression stage is specifically:
[0114] After the addition of glycerol stops, after the dissolved oxygen DO rebound is observed, 4g / L of methanol is added and 12ml / L of PTM1 is added to the methanol; after the methanol to be added is consumed (DO rebound), methanol is started to be added in a DO-Spike manner, and the DO-Spike response time is less than 60 seconds, and the DO value is controlled at 10-30; at the same time as the methanol is started, the temperature is adjusted to 24°C; the pH is controlled at the project specified pH 5.7; and DO-Spike is performed every 12 hours, and the response time and other fermentation data are recorded; sampling is performed every 12 hours, the pH and the wet weight of the engineered bacteria are tested, centrifuged, 100μl of the supernatant is added to the electrophoresis buffer, boiled at 100°C for 5 minutes, and stored at -20°C; the remaining supernatant is stored in a refrigerator at 2-8°C for detection or electrophoresis analysis; the samples are marked when sampling; during the induction expression stage, the methanol concentration in the fermentation liquid in the tank is maintained between 0.2-0.9%.
[0115] The specific operation process and experimental data of a human serum albumin fermentation process of this embodiment are as follows:
[0116] The materials and equipment used include:
[0117] 1. Bacteria
[0118] 1. Pichia pastoris host strain GS115 (Pichia pastoris (his4) NRRL Y-15851);
[0119] 2. Pichia pastoris host strain CBS7435 (Pichia pastoris NRRL Y-11430);
[0120] 3. Escherichia coli host bacteria:
[0121] E.coli JM109 F'[(recA1, supE44endA1hsdR17gyrA96 relAl thi△(lac-proAB)
[0122] F'[traD36 proAB*lacI a lacZ△M15]);
[0123] E. coli HB101(supE44 hsd S20(rB-mB-)recA:ara-14proA2lac Y:galK2rpsL20xyl-5mtl-1).
[0124] The above E. coli host bacteria are used for cloning of target genes and construction and preparation of plasmids.
[0125] 2. Main Reagents
[0126] 1. DNA restriction endonucleases, T4 DNA ligase, polymerase, etc. were purchased from GIBCO-BRL, Pharmacia, Bio-Labs, and Huamei Bioengineering Co., Ltd.;
[0127] 2. Casein hydrolysate (product of MERK, Germany);
[0128] 3. Bacto-yeast extract (product of Difco, USA);
[0129] 4. PCR amplification kit (product of Pharmacia, Sweden);
[0130] 5. DNA sequence analysis kit (product of USB Company, USA);
[0131] 6. Acrylamide (Acr), N,N-dimethylbisacrylamide (Bis), sodium dodecyl sulfate (SDS), guanidine hydrochloride, urea, TEMED (products of Sigma, UK);
[0132] 7. IPTG, X-gal, DTT, Agarose (products of Sigma, UK);
[0133] 8.YNB, Biotin, Agar (products of Difco, USA);
[0134] 9. Sorbitol, glucose, L-histidine, L-lysine, L-methionine, L-leucine, L-isoleucine, L-glutamic acid (products of Sigma, USA);
[0135] 10. Glycerol, methanol (Shanghai Chemical Reagent Factory);
[0136] 11. Enzyme reaction solution:
[0137] Restriction endonuclease high salt buffer: 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM MgCl2;
[0138] Restriction endonuclease neutral salt buffer: 50mM Tris-HCl (pH 7.5), 50mM NaCl, 10mM MgCl2;
[0139] Restriction endonuclease low salt buffer: 10 mM Tris-HCl (pH 8.0), 10 mM MgCl2;
[0140] T4 DNA ligase buffer: 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 10 mM DTT, 1 mM ATP;
[0141] 13.SDS-PAGE protein electrophoresis reagent:
[0142] Electrophoresis buffer: 192 mM glycine, 25 mM Tri-HCl, 0.1% SDS, pH 8.3;
[0143] Stacking gel buffer: 125 mM Tris-HCl, 0.1% SDS, pH 6.8;
[0144] Separation gel buffer: 375 mM Tris-HCl, 0.1% SDS, pH 8.8;
[0145] Sample buffer (1×): 50 mM Tris-HCl (p6.8), 1% SDS, 10% glycerol, 2.5% mercaptoethanol, 0.05% bromophenol blue;
[0146] 30% acrylamide: 29% acrylamide, 1% N, N-dimethylbisacrylamide;
[0147] Coomassie Brilliant Blue staining solution: 0.25% (W / V) Coomassie Brilliant Blue G-250, 5% Hac;
[0148] 45% ethanol decolorizing solution: 7.5% HAc, 10% ethanol;
[0149] 13. Commonly used buffers:
[0150] TE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA;
[0151] STE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 20 mM NaCl PBS buffer: 10 mM NaH, POq-Na, HPO3 (pH 7.0), 150 mM NaCl;
[0152] 10X TBS buffer: 108 g Tris base, 55 g boric acid, 40 ml EDTA (0.5 M), pH 8.0 per liter;
[0153] 50X TAE buffer: 242 g Tris base, 57.1 ml glacial acetic acid, 100 ml EDTA (0.5 M), pH 8.0 per liter;
[0154] Saturated phenol: saturate with TE buffer after redistillation, store in aliquots at 20°C;
[0155] Phenol:chloroform:isoamyl alcohol (V / V):1:1:0.8;
[0156] Chloroform:isoamyl alcohol (V / V):24:1.
[0157] 3. Main instruments and equipment
[0158] 1. ABI381A automatic DNA synthesizer, a product of Applied Biosystems (ABI), USA;
[0159] 2.5L RIBE-5 fully automatic fermentation tank, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd.;
[0160] 3.15L Biocenter 15F fully automatic fermenter, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd. (software system: Fermentation Star);
[0161] 4.50L Biocenter 50F fully automatic fermenter, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd. (software system: Fermentation Star);
[0162] 5. 100L Biocenter 100F fully automatic fermenter, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd. (software system: Fermentation Star);
[0163] 6.500 liters fully automatic Bplus bioreactor, a product of B. Braun, Germany;
[0164] 7. SDL-100 protein purification system, Suzhou Saipu Instrument Co., Ltd. (medium pressure chromatography workstation, software SCG);
[0165] 8. Agilent High Performance Liquid Spectrometer, Agilent Technologies, 1260infinity, a product of Agilent, USA;
[0166] 9. External pressure ultrafiltration membrane assembly (filtration accuracy: 30KD), product of Huzhou Keli Membrane Technology Co., Ltd.;
[0167] 10. External pressure ultrafiltration membrane assembly (filtration accuracy: 100KD), product of Huzhou Keli Membrane Technology Co., Ltd.;
[0168] 11. Full wavelength microplate reader, Thermo Fisher 1510, a product of Thermo Fisher Scientific, USA;
[0169] 12. Electroporation instrument, Micropulser411BR10654, BIO-RAD, USA.
[0170] IV. Experimental Methods
[0171] (I) Culture medium and culture conditions
[0172] Escherichia coli culture medium LB (1% bacto-typtone, 0..5% bacto-yeast extract, 1% NaCl), solid culture medium plus Agar powder 15g / L, Escherichia coli cultured at 37°C; Pichia pastoris rich culture medium YPD (1% Yeast extract, 2% peptone, 2% dextrose); Pichia pastoris protoplast regeneration medium RBD [1Msorbital, 1% dextrose, 1.34% YNB, 4×10 5Biotin, 0.005% amino acid mixture (including L-glutamic acid, L-methionine, L-leucine, L-isoleucine, L-lysine)], if it is a solid culture medium, add 2% Agar powder to the liquid culture medium; Pichia pastoris shake flask medium BMGY and BMMY (1% yeast extract, 2% peptone, 100mM PBS buffer, pH 6.0, 1.34% YNB, 4X105% Biotin, 1% glycerol or 0.5% methanol). Pichia pastoris was cultured at 30°C.
[0173] (II) High-density fermentation medium and culture conditions of Pichia pastoris fermenter:
[0174] A. 10×Basal Salts:
[0175] 1.H3PO4, 85% 42ml
[0176] 2.CaSO2·2H2O 1.8g / L
[0177] 3.K2SO4 28.6g / L
[0178] 4.MgSO4·7H2O 23.4g / L
[0179] 5.KOH 6.5g / L
[0180] B.250×PTML salts:
[0181] 1.CuSO4·5H2O 6g / L
[0182] 2. KI 0.08g / L
[0183] 3.MnSO4·H2O 3g / L
[0184] 4.Na2MoO4·2H2O 0.2g / L
[0185] 5.H3BO3 0.02g / L
[0186] 6.CoCl2 0.5g / L
[0187] 7. ZnCl2 20g / L
[0188] 8.FeSO4·7H2O 65g / L
[0189] 9. Biotin 0.2g / L
[0190] 10.H2SO4 5ml
[0191] C.glycerol 8%(V / V)
[0192] D.Feed medium 50%glycerol(1L)+12ml / L PTM1
[0193] E.Induced medium 100% methanol(1L)+12ml / L PTM1
[0194] F.Dissolved O2(DO) >20%
[0195] G. pH 5.0-5.8
[0196] H.Temperature 20-30℃
[0197] (III) High-density fermentation medium and culture conditions of Pichia pastoris fermenter 2: Preparation of liquid A:
[0198] YPD medium (50 ml):
[0199] 1. Yeast extract 0.5g
[0200] 2. Peptone 1g
[0201] 3. Glucose 1g
[0202] The above YPD medium was used for the cultivation of primary seed bacteria of Pichia pastoris.
[0203] Preparation of Solution B:
[0204] BSM medium (1L):
[0205] 1. 98% glycerol 63g / L
[0206] 2. ddH2O (ultrapure water) 912ml
[0207] 3. CaSO2·2H2O 0.46g / L
[0208] 4. MgSO4·7H2O 5.84g / L
[0209] 5. K2SO4 7.34g / L
[0210] 6. (NH4)2SO4 9g / L
[0211] The BSM medium is used for the cultivation of secondary seed bacteria of Pichia pastoris and as the main nutrient medium for yeast cultivation in a bioreactor.
[0212] Preparation of Solution C:
[0213] Preparation of sodium hexametaphosphate (HMP) solution (150ml):
[0214] 1. (NaPO3)6(Sodium hexametaphosphate) 30g
[0215] 2. ddH2O (ultrapure water) 150ml
[0216] Preparation of Solution D:
[0217] PTM1 solution (1L):
[0218] 1.CuSO4·5H2O 6g / L
[0219] 2. KI 0.08g / L
[0220] 3.MnSO4·H2O 3g / L
[0221] 4.Na2MoO4·2H2O 0.2g / L
[0222] 5.H3BO3 0.02g / L
[0223] 6.CoCl2 0.5g / L
[0224] 7. ZnCl2 20g / L
[0225] 8.FeSO4·7H2O 65g / L
[0226] 9. Biotin 0.2g / L
[0227] 10.H2SO4 5ml
[0228] (IV) Plasmid extraction
[0229] 1. Small-scale plasmid extraction
[0230] Pick a single clone of bacteria and inoculate it into 2 ml of LB medium containing the corresponding antibiotics, and shake it at 37°C overnight. The next day, take 1.5 ml of the bacterial solution into an Eppendorf tube, centrifuge and precipitate the bacteria, and remove the supernatant. Place the bacterial pellet in an ice bath, add 100 μl of solution I (50 mM Glucose, 25 mM Tris-HCl, 10 mM EDTA, pH 8.0) in turn, shake and mix, and incubate at room temperature for 5 minutes; add 200 μl of solution II (0.2N NaOH, 1% SDS), turn over and mix, and ice bath for 5 minutes; add 150 μl of solution III (3M NaAc, pH 4.8), shake and mix gently, and ice bath for 5 minutes; add 450 μl of redistilled phenol / chloroform (1:1), mix and centrifuge at 12,000 rpm for 10 minutes, carefully aspirate the upper aqueous phase into 2 volumes of pre-cooled anhydrous ethanol, place in a -20°C refrigerator for 2 hours, and centrifuge at 12,000 rpm. After 15 minutes, remove the ethanol, carefully add 500μl 70% ethanol to wash and remove the salt, centrifuge and drain, add 18μl TE and 2μl RNAase enzyme solution, and keep at 37℃ for 1 hour for enzyme digestion identification and further cloning.
[0231] 2. Large-scale plasmid extraction
[0232] Take 500 ml of overnight culture solution, centrifuge at 5000 rpm for 10 min at 4°C, add 100 ml of STE, wash with suspension, and centrifuge to collect the cells. Then add solution I (50 mM Glucose, 25 mM Tris-HCl, 10 mM EDTA, PH
[0233] 8.0) 18ml, lysozyme (10mg / ml, 1% SDS) 2ml, incubate at room temperature for 10min; add solution II (0.2NNaOH, 1% SDS) 40ml, mix gently (until the bacterial solution is transparent), ice bath for 5min; then add solution III (3MNaAc, pH
[0234] 4.8) 20ml, mix well and place in ice bath for 10min; extract twice with an equal volume of phenol:chloroform (1:1) solution, add 2 times volume of pre-cooled anhydrous ethanol at -20℃ and place overnight, centrifuge at 12,000rpm for 15min, discard the supernatant, wash the precipitate with 70% ethanol 1-2 times, drain and dissolve with 3ml TE, add 10μl of RNase solution (10mg / ml), keep at 37℃ for 30min, apply to Sepharose2B chromatography column (1X10cm, balanced with TE), and use TE (pH7.6) as eluent to collect the first peak (high molecular weight DNA). After the collected sample volume is measured, 2 times the volume of pre-cooled anhydrous ethanol and 1 / 10 volume of 3M NaAc (pH 5.2) are added, mixed and placed in a -20°C refrigerator overnight, centrifuged at 12,000rpm for 15min, the supernatant is discarded, the precipitate is washed 1-2 times with 70% ethanol, drained and dissolved in 1ml TE, and an appropriate amount of solution is taken to measure the DNA content with an ultraviolet spectrophotometer at 260nm. The large-scale extracted recombinant plasmid DNA can be used for the protoplast method of the present invention to transform the Pichia host bacteria and for long-term low-temperature storage.
[0235] (V) Preparation of E. coli competent cells and transformation of recombinant plasmids
[0236] Inoculate the E. coli host bacteria into 2 ml LB culture medium and shake at 37°C overnight. The next day, take 500 ml of overnight bacteria and inoculate into 50 ml LB culture medium, shake and culture at 37°C and 300 rpm for 1 hour, until the cell density reaches 0.5 OD600. Centrifuge at 5000 rpm for 5 minutes at 4°C, pour off the supernatant, suspend the cells with 25 ml of cold solution containing 100 mM CaCl2, 10 mM Tris-HCl (pH 7.4), place in an ice bath for 30-60 minutes, then centrifuge at 4°C and 5000 rpm for 5 minutes, carefully pour off the supernatant, suspend the cells with 2 ml of cold calcium chloride solution, place in an ice bath for 40 minutes, and then use for transformation.
[0237] Take 200 μl of the above freshly prepared competent E. coli cells and suspend them in an Eppendorf tube, add an appropriate amount of recombinant plasmid DNA ligation solution 10 μl, ice bath for 30 minutes, and heat shock at 42°C for 2 minutes; add 500 μl LB culture medium, shake slowly on a shaker at 37°C for 1 hour, centrifuge at 10,000 rpm for 10 seconds, pour off most of the LB, retain about 200 μl LB, gently mix the bacterial suspension with a pipette tip, divide it into 50 μl and 150 μl, apply each to an LB agarose plate containing 50 μg / ml ampicillin, and culture in a 37°C incubator for 8-16 hours.
[0238] The method for preparing high-purity recombinant human serum albumin in this embodiment comprises the following steps:
[0239] S1. Prepare a novel host bacterium, wherein the novel host bacterium is deposited in the General Microbiological Center of China Microorganism Culture Collection Administration, with a deposit number of CGMCC No. 30175 and a deposit date of March 28, 2024;
[0240] S2, fermentation;
[0241] S3. Purification.
[0242] The novel host bacteria is an engineered bacterium expressing gene recombinant HSA obtained by introducing a recombinant expression vector into Pichia pastoris CBS7435 strain. The nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO:1.
[0243] The fermentation in step S2 specifically includes
[0244] S210, preparing culture medium;
[0245] S220, electrode calibration;
[0246] S230, feeding;
[0247] S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin;
[0248] S250, fermentation;
[0249] S260, place the can.
[0250] The recombinant expression vector comprises:
[0251] (1) A 5' regulatory region derived from Pichia pastoris, comprising a promoter element, wherein the 5' regulatory region is selected from the alcohol oxidase AOX1 gene, the dihydroxyacetone synthase DAS1 gene or the histidinol dehydrogenase HIS4 gene derived from Pichia pastoris, and the 3' end of the regulatory region is connected to the sequence of (2) below;
[0252] (2) An optimized gene encoding human serum albumin, wherein the nucleotide sequence contained therein is as shown in SEQ ID NO:2, and the amino acid sequence contained therein is as shown in SEQ ID NO:3;
[0253] (3) A 3' terminator sequence derived from methanolic yeast, wherein the 3' terminator sequence is selected from the 3' terminator sequence of AOX1 gene, AOX2 gene or His4 gene derived from Pichia pastoris.
[0254] For the optimized gene encoding human serum albumin, the nucleic acid sequence length is 1755bp, and the corresponding encoded amino acid sequence is 585 amino acids. It is one of the longest functional genes chemically synthesized internationally to date.
[0255] The present invention relates to a specific and novel optimization design of the HSA gene, and the three core databases of molecular biology are used in the design: 1. International Nucleotide Sequence Database (GenBank / EMBL / DDBJ); 2. Swiss Protein Sequence and Annotation Database (Swiss-PROT); 3. Protein and Biomolecule Three-Dimensional Structure Database (Protein Data Bank, PDB) provided by Brookhaven National Laboratory in the United States. Then, multiple computer software packages (including GENESIS and PROSIS software packages compiled by Genetic Computer Group of University of Wisconsin, the United States, Caltec software package compiled by California Institute of Technology, the DNASIS and PROSIS software packages provided by Pharmacia, Sweden, and other programs) are used for multi-faceted auxiliary analysis, and finally the optimized gene encoding human serum albumin is obtained.
[0256] Among them, it also includes
[0257] At least one marker gene that can be selected in E. coli;
[0258] A DNA fragment with a replication origin capable of replicating in an E. coli host bacterium;
[0259] The invention also comprises at least two marker genes which can be selected in yeast.
[0260] In the optimized gene encoding human serum albumin, the preferred codons of the alcohol oxidase (AOX1) gene of Pichia pastoris are selected and the preferred codons of the gene are controlled to account for 90% of the total number of codons of the optimized gene.
[0261] In the optimized gene encoding human serum albumin, three restriction endonuclease sites, SalI, Hind III and Xba I, are sequentially inserted from 5' to 3' inside the optimized gene, so that the optimized gene is relatively evenly divided into four large fragments, which is convenient for splicing, cloning and assembly of synthetic genes.
[0262] In the optimized gene encoding human serum albumin, continuous GC pairing is reduced and AT pairing preferred by Pichia pastoris is increased, so that the GC content inside the optimized gene is adjusted to 45-50%. In this embodiment, the optimal ratio is preferably 47.64%, which is conducive to the high expression of the target gene (see Figure 1 ).
[0263] The optimized gene encoding human serum albumin also includes an expression reading frame of
[0264] The restriction endonuclease BamHI site at the 5' end was inserted into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxyoligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e. AXXATG), and then the yeast a-mating child leader peptide (consisting of 85 amino acids) sequence from Saccharomyces cerevisiae, and then the HSA mature gene was inserted between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector;
[0265] The coding sequence AAAAGA of two double basic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene, and the specific sequence is SEQ ID NO:4; the double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene, and the specific sequence is SEQ ID NO:5. Figure 2 ; The coding sequence AAAAGA of two double basic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene for processing and cleavage by the yeast endogenous KEX-2 protease; the double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene to strengthen the termination signal of translation and prevent read-through during gene expression.
[0266] The mature gene (1755 bp) encoding human serum albumin synthesized by chemical digestion was cut out from the pUC18 cloning vector by EcoRI-SmaI double restriction enzyme digestion, and the fragment was identified by 1% agarose gel electrophoresis. Figure 3 (A: Lane 1 represents the recombinant plasmid; Lane 2 represents the recombinant plasmid digested with EcoRI and SmaI; Lane M represents the molecular weight standard KB Ladder. B: The two lanes represent the molecular weight standard KB Ladder and DL3000, respectively), which is consistent with the expected results; the KpnI of the multiple cloning site of the pUC18 cloning vector was changed to NotI; the chemically synthesized mature gene encoding human serum albumin (1755bp) was cut out from the pUC18 cloning vector by double digestion with EcoRI-NotI, and the corresponding size gel strips were cut out and the target gene fragment was recovered using a DNA recovery kit. The HSA fragment cut from the pUC18 cloning vector with double digestion with EcoRI-NotI was cloned into the Pichia pastoris recombinant expression vector pPIC9K cut with the corresponding double digestion to construct the recombinant expression vector HSA-pPIC9K (containing the HSAEcoRI-NotI fragment). The specific flowchart of the recombinant vector is shown in the figure. Figure 4, the connection reaction system is:
[0267]
[0268]
[0269] Ligation was performed overnight at 16°C in a 20 μl reaction system.
[0270] The above-mentioned ligation solution containing the recombinant plasmid HSA-pPIC9K was added with two concentrations of 4 μl and 8 μl to transform the competent E. coli JM109 host bacteria, spread on LB (containing 20 μg / ml ampicillin) plates, and cultured in a 37°C incubator overnight. Then, 18 colonies containing the recombinant plasmid HSA-pPIC9K were randomly selected and inoculated with 2 ml LB (containing 20 μg / ml ampicillin), respectively, and shaken on a shaker for 6-8 hours. The double-stranded DNA of the plasmid was quickly extracted by alkaline denaturation, and then double-digested with EcoRI-NotI, and 1% agarose agarose gel electrophoresis was performed to identify the recombinants containing the HSA gene of the corresponding size, among which 5 clones containing the HSA EcoRI-NotI fragment were identified. A large amount of HSA-pPIC9K recombinant plasmid was extracted from the inoculum of the E. coli host bacteria containing the HSA-pPIC9K recombinant plasmid identified above by the large-scale plasmid extraction method for long-term storage or subsequent transformation into the Pichia pastoris host bacteria. The specific design details and sequencing results of constructing the HSA-pPIC9K recombinant plasmid are shown in Figure 4 and Figure 5 , 6 、7.
[0271] The recombinant plasmid is linearized by restriction enzyme SacI or Bgl II, and the linearized recombinant plasmid is used to transform the Pichia pastoris host bacteria, that is, the transformed host bacteria GS115 or CBS7435, by electrotransformation method. The specific implementation method is as follows:
[0272] a. Culture medium preparation
[0273] 1. BMGY medium: 10 g yeast powder, 20 g peptone, dissolved in 700 mL deionized water, sterilized by wet heat for 20 min, after cooling, add 100 mL 1 M, pH 6.0, potassium phosphate buffer, 100 mL 10×YNB, 2 mL 500×B, 100 mL 10×GY, and store at 4°C.
[0274] 2. BMMY medium: 10 g yeast powder, 20 g peptone, dissolved in 700 mL deionized water, sterilized by wet heat for 30 min, after cooling, add 100 mL 1 M pH 6.0 potassium phosphate buffer, 100 mL 10×YNB, 2 mL 500×B, 100 mL 10×M, and store at 4°C.
[0275] 3.MD medium: add 100mL 10×YNB, 2mL 500×B, and 100mL 10×D to 800mL sterile water and store at 4℃.
[0276] 4.1M, pH 6.0 potassium phosphate buffer: 132mL 1M K2HPO4, 868mL 1M KH2PO4, pH 6.0, sterilize by moist heat, store at 4°C.
[0277] 5.10×YNB: Dissolve 134 g of YNB (containing ammonium sulfate) in 1000 mL of deionized water, filter and sterilize, and store at 4°C.
[0278] 6.500×B: Dissolve 20 mg of Biotin in 100 mL of deionized water, filter and sterilize, and store at 4°C.
[0279] 7.10×M: Mix 5 mL of methanol with 95 mL of deionized water, filter and sterilize, and store at 4°C.
[0280] 8.10×GY: Mix 100 mL of glycerol with 900 mL of deionized water, sterilize by moist heat, and store at 4°C.
[0281] 9.10×D: Dissolve 100 g glucose in 1000 mL deionized water, filter and sterilize, and store at 4°C.
[0282] 10.1M sorbitol: 18.2g D-sorbitol dissolved in 100mL deionized water, sterilized by filtration, and stored at 4℃ b. Bacteria preparation
[0283] 1. Pick a single colony of Pichia pastoris (GS115 or CBS7435), inoculate it into a 50ml Erlenmeyer flask containing 5ml YPD medium, and culture it overnight at 30℃ and 250-300r / min;
[0284] 2. Take 100-500 μl of the culture and inoculate it into a 2L triangular shake flask containing 500 ml of fresh culture medium. Culture overnight at 28-30°C and 250-300 r / min until the OD600 reaches 1.3-1.5.
[0285] 3. Centrifuge the cell culture at 1500g for 5 min at 4°C and resuspend the cell pellet in 500 ml of ice-cold sterile water;
[0286] 4. Centrifuge as in step 3 and resuspend the bacterial pellet in 250 ml of ice-cold sterile water;
[0287] 5. Centrifuge as in step 3 and resuspend the bacterial pellet in 20 ml of ice-cold 1 M sorbitol solution;
[0288] 6. Centrifuge as in step 3 and resuspend the bacterial pellet in 1 ml of ice-cold 1 M sorbitol solution to a final volume of about 1.5 ml;
[0289] Note: It can be packaged into 80μl packages and frozen, but its transformation efficiency will be affected (within 2 weeks).
[0290] c. Electroporation
[0291] 1. Add 80 μL of treated Pichia competent cells and 5-20 μg of linearized DNA (dissolved in double distilled water, volume 5-10 μL) into a 1.5 mL pre-cooled centrifuge tube and mix well. Then transfer the mixture into a transformation cup (0.2 cm type) in a pre-ice bath;
[0292] 2. Ice-bath the transformation cup containing the transformation mixture for 5 minutes;
[0293] 3. According to the information provided by the electroporation instrument, refer to other literature and multiple explorations, determine the appropriate voltage, current, capacitance and other parameters, and perform electroporation according to the optimized parameters; the relevant parameters preferentially recommended by the present invention are: voltage 1500-1800V; capacitance 25μF; resistance 200-400Ω, and electroporation time 4-10msec.
[0294] 4. Immediately after the pulse, add 1 mL of 1 M sorbitol solution in an ice bath to the transformation cup, and then transfer the transformation solution to a new 1.5 mL centrifuge tube;
[0295] 5. Incubate in a shaking incubator at 28°C for 1 to 2 hours;
[0296] 6. Pipette 50-200 μL of the transformation solution of Pichia pastoris host bacteria GS115 or CBS7435 and coat the MD plate;
[0297] 7. Culture in a 28°C incubator for about 3-4 days until many monoclonal positive colonies (yeast transformants) containing the recombinant plasmid appear.
[0298] d. Screening of multi-copy transformants
[0299] 1. Use 2 mL of sterile water to fully rinse the MD plate on which the yeast transformants grew, and then use a pipette to draw up the bacterial solution and temporarily store it in a centrifuge tube;
[0300] 2. The obtained bacterial solution was spread on a YPD plate containing G418 resistance, with 100 μL of bacterial solution spread on each plate; the G418 antibiotic content was configured into different concentration gradients: 0.25%, 0.5%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0%, etc.;
[0301] 3. Place the plate coated with the bacterial solution in a 28°C incubator for 4 to 12 days to grow white monoclonal colonies with different G418 resistance (i.e., obtain Pichia pastoris transformants with different copy numbers).
[0302] The results of the experiment of electroporation of host bacteria GS115 or CBS7435 in this example are as follows: Figure 8 , Fig. 9 , Fig.10 , as shown in Table 1 and Table 2.
[0303] Table 1 Results of multi-copy screening experiment of Pichia pastoris GS115 engineering strain
[0304]
[0305] Note: In Table 1, the G418 resistance of 0.25 means that the host bacteria contains 1 copy of the exogenous gene, and so on.
[0306] Table 2 Results of multi-copy screening experiment of Pichia pastoris CBS7435 engineering strain
[0307]
[0308]
[0309] Note: In Table 2, G418 resistance of 0.25 means that the host bacteria contains 1 copy of the exogenous gene, and so on.
[0310] The transformants containing recombinant plasmid HSA-pPIC9K with different copy numbers selected by electrotransformation were randomly selected from 6 clones on the YPD culture plate, and the single colonies were inoculated into a test tube containing 4 ml of BMGY liquid culture medium, and shaken overnight at 28°C, 200-250rpm. The bacterial solution in the test tube was centrifuged at 1500-3000g for 5 minutes at room temperature, the bacteria were collected, and the bacteria were resuspended with 4 ml of the original culture volume of BMMY, and shaken at 28°C, 250-300rpm, and shaken for 36-48 hours; centrifuged at 5000rpm for 10 minutes, 30 μL of supernatant was taken, vacuum-dried, and the samples were identified by 10% SDS-PAGE electrophoresis, and the pPIC9K empty vector expression was used as a control to identify the high-expression clones. Then, these high-expression clones screened out were kept at low temperature with 15% glycerol and used as engineering strains for further expression experiments.
[0311] For the above-mentioned engineered high-expression strain, a small-scale induction experiment was carried out. If it was a Pichia pastoris GS115 strain, the experimental scheme would follow the steps of glycerol bacteria → YPD → BMGY → BMGY → BMMY: after the glycerol bacteria were inoculated in YPD liquid culture medium for rejuvenation, 1 ml of the seed bacteria solution was transferred to 50 ml of BMGY culture medium, and the culture was shaken at 28° C., 200-250 rpm for 18-24 hours; then 40 ml of the seed bacteria was inoculated into 1000 ml of BMGY culture medium at a 4% inoculation amount, and the culture was shaken at 28° C., 250-300 rpm for 24-30 hours; the culture solution was centrifuged at 5000 rpm for 5 min, the supernatant was discarded, and then the bacteria were suspended in 500 ml of BMMY induction expression culture medium, placed at 28° C., 250-300 rpm, and the shaker was shaken for 3-4 days, and supplemented every 24 hours (100% methanol was added to a final concentration of 0.5%). At this time, the cell density of Pichia pastoris engineering bacteria has generally reached 18-20 OD 600 Most of the exogenous proteins expressed by the gene were secreted into the liquid culture medium. The fermentation medium was centrifuged at 4°C 10000rpm for 20min, the bacteria were discarded, and the supernatant containing a large amount of HSA expression products was identified by SDS-PAGE electrophoresis. This small induction experiment was used to analyze and identify the expression level of recombinant HSA.
[0312] For the above-mentioned engineered high-expression strains, a small-scale induction experiment was conducted. If it was the Pichia pastoris CBS7435 strain, the experimental plan would follow the steps of glycerol bacteria → YPD → YPD → BSM → BSM: the sample loading amount was similar to that of the GS115 strain.
[0313] In this example, some results of the small-scale induction experiment on some Pichia pastoris GS115 or CBS7435 strains are shown in Fig.11 , 12 and Fig.13 , 14 .
[0314] The engineered strains with obvious expression bands in the above-mentioned small-scale induction experiment were further cultured and fermented in 5L, 30L, 50L, and 500L fermenters using fed-batch fermentation (Fed-bach-fermentation) at high cell density, with the aim of exploring the Pichia pastoris BSM fermentation process and further verifying the pilot fermentation process of the GS115 or CBS7435 engineered strains after electroporation. The specific implementation plan is as follows:
[0315] S210, preparing culture medium;
[0316] The fermentation substrate culture medium of this embodiment is prepared as shown in the following Table 3.
[0317] Table 3 Fermentation substrate medium preparation (prepared according to 6L volume)
[0318]
[0319] When preparing the fermentation substrate culture medium, store phosphoric acid and glycerol separately in a measuring cup or beaker. Dissolve other inorganic salts in about 2L of purified water in sequence, that is, add the next reagent after the previous reagent is completely dissolved. The last KOH also needs to be dissolved separately and not mixed with the inorganic salts.
[0320] S220, electrode calibration, electrode calibration includes pH electrode calibration and dissolved oxygen electrode calibration.
[0321] pH electrode calibration: first prepare pH6.86 and 4.00 standard pH electrode solution, washing bottle and paper towel. Connect the pH electrode to the fermentation tank electrode line, rinse the electrode with a washing bottle, absorb water with a paper towel, insert the pH6.86 electrode solution, and after the pH value displayed by the fermentation tank is stable, press the calibration key to calibrate the 0 point. Take out the electrode, rinse the electrode with a washing bottle, absorb water with a paper towel, insert the pH4.00 electrode solution, and after the displayed pH value is stable, press the calibration key to calibrate the slope. Repeat this operation 3 times, the pH display value should be consistent with the value of the electrode solution, and the pH electrode calibration is completed.
[0322] Dissolved oxygen electrode calibration: Connect the dissolved oxygen electrode to the fermentation tank electrode line, clean it, and insert it into a saturated anhydrous sodium sulfite solution. After standing for 15 minutes, the dissolved oxygen display value should no longer change. At this time, press the calibration key to calibrate the dissolved oxygen 0 point. The slope of the dissolved oxygen electrode is calibrated to 100% fixed slope before fermentation inoculation, with 100rpm stirring and 0.5vvm ventilation, and a tank pressure of 0.05MPa, to complete the calibration of the dissolved oxygen electrode.
[0323] S230, feeding.
[0324] Feeding process: add phosphoric acid and glycerol to the fermentation tank in sequence, then add inorganic salt solution, and finally add KOH, and add purified water to make up to 5L (reference tank weight is about 5Kg, and it should be about 6L after sterilization). After the feeding is completed, the pH value should be below 2. Prepare a total of 1L of PTM1. Seal and store in a dark place.
[0325] 100% analytical grade methanol 3L;
[0326] 50% glycerol supplement 800ml:
[0327] Weigh 400 g of 98% glycerol, add purified water to make up to 800 ml, pour into a 1 L feeding bottle after dissolving, sterilize at 121°C for 30 minutes, and cool for later use.
[0328] S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin;
[0329] Pichia pastoris engineered strain fermentation experiment process
[0330] 1. Seed bacteria preparation:
[0331] Take the glycerol bacteria numbered CBS7435-C1-C50 or GS115-G1-G30, add 100μl to 20ml of bacterial solution to 100ml YPD medium as the first-level seed solution, and culture it at 28℃ and 200rpm for 24 hours; transfer 5ml of bacterial solution to YPD480ml / 2L conical flask as the first-level seed solution, and continue to culture it at 28℃ and 200rpm for 24 hours. Transfer 5ml of the first-level seed bacteria solution to BSM medium 480ml / 2L conical flask (2 bottles in total) as the second-level seed solution, and continue to culture it at 28℃ and 200rpm for 24 hours. The OD of this second-level seed bacteria solution before inoculation is 0.1877777. 600 It should be between 20 and 40.
[0332] Inoculate the fermenter:
[0333] Before inoculation, confirm that the temperature of the fermentation tank is 30℃, set the pH to 5.0, adjust the pH automatically with ammonia water, and then use the flame circle inoculation method to connect the seed liquid to the fermentation tank to complete the inoculation. For flame circle inoculation, surround the fermentation tank inoculation port with alcohol cotton balls and ignite it. Close the air inlet valve and open the exhaust valve until the tank pressure is about 0.02MPa. Use a special tool to slightly open the inoculation port, exhaust a small amount of air until there is no sound of air flowing out, and then completely unscrew the inoculation port. Open the packaging rope of the seed bacteria bottle and PTM1 container, remove the sealing film above the flame circle, and then pour the seed bacteria and PTM1 into the tube. Do not mix the seed bacteria and PTM1 before inoculation.
[0334] Recombinant human serum albumin fermentation culture stage:
[0335] (1) Basic culture stage of engineering bacteria
[0336] At the beginning of the fermentation of engineered bacteria, the SCADA process control software was started to record data, fermentation time and batch number, and the map record was turned on; from the time the inoculated bacteria were put into the fermentation tank, the relevant fermentation data (such as time, temperature, stirring, pH, DO, air flow, tank pressure) were recorded regularly every 4 hours; the control parameters were set as follows: pH was controlled at 5.5±0.1 with ammonia water, and the temperature was controlled at 28±1℃; DO value was controlled above 30, air flow was 2vvm, and tank pressure was controlled at 0.03-0.04Mpa; after DO rebound (DO rebound refers to the DO value rising by more than 10 without any operation of the fermentation tank ventilation, stirring, and tank pressure), it entered the transition culture phase; sampling was taken to detect OD during the rebound 600 It should be around 50.
[0337] (2) Transitional culture stage of engineered bacteria:
[0338] The transition culture phase of engineered bacteria is to further increase the biomass of engineered bacteria. Fermentation data is recorded every hour. During the transition culture phase, 50% glycerol needs to be added: after DO rebounds, 50% glycerol is added immediately (add 12ml / L of PTM1 solution containing biotin, approximately 10ml); at the same time, the stirring is adjusted to the maximum speed specified by the fermenter, the air flow is adjusted to 2vvm, and the tank pressure is adjusted to 0.04-0.08Mpa; under this condition, the feeding rate is to control the DO value at 30±10. Perform DO-Spike at least once every hour to ensure that the DO-Spike response time is less than 60 seconds. The addition cycle is about 4-5 hours; when adding glycerol, adjust the pH set value on average every hour so that the pH is the induced pH value required by the project after the glycerol feeding is completed (for this fermentation, the pH in the induction stage is the same as the pH in the culture stage, both are 5.7, so there is no need to adjust the pH); at the end of the transition culture phase, OD 600 At this time, the wet weight of the bacterial solution was tested and the sample was kept for 0 h. After that, the wet weight was tested instead of OD. The glycerol addition was stopped and the methanol induction stage was started.
[0339] (3) Engineering bacteria induced expression stage:
[0340] After stopping the addition of glycerol and observing the rebound of dissolved oxygen DO, prepare to add methanol (add 12ml / L of PTM1 to methanol); add 4g / L of methanol at one time (24g of methanol was added at one time in this experiment, and 30ml of methanol can be added through the feed gasket with a disposable syringe). After the added methanol is consumed (DO rebound), start to add methanol in DO-Spike mode. The DO-Spike response time is preferably less than 60 seconds, and the DO value is controlled at 10-30; at the same time as the addition of methanol, adjust the temperature to the project specified temperature (the induction temperature of this experiment is 24℃); control the pH at the project specified pH5.7; during the induction expression phase of the engineering bacteria, do DO-Spike every 12 hours, and record the response time and other fermentation data; take samples every 12 hours, test the pH and wet weight of the engineering bacteria, centrifuge, take 100μl of the supernatant and add electrophoresis buffer, boil at 100℃ for 5 minutes, and store at -20℃; the remaining supernatant is stored in a refrigerator at 2-8℃ for detection or electrophoresis analysis; mark the samples when sampling. During the entire Pichia yeast engineering bacteria induction expression phase, maintain the methanol concentration in the tank culture medium between 0.2-0.9%.
[0341] (4) Place the can
[0342] Pichia pastoris engineered strain tank fermentation experiment: the induction expression time of this experiment is about 200 hours, followed by tank release, solid-liquid separation and subsequent treatment; and the supernatant is collected for subsequent purification.
[0343] The detection of the target protein in the fermentation test of Pichia pastoris is as follows:
[0344] In this embodiment, the fermentation process of Pichia pastoris in the fermenter is controlled and recorded in real time, especially the target protein in the fermentation broth in the fermenter is tracked and detected online at different time points in the induction expression stage: the present invention uses the BCA protein concentration determination kit (Enhanced BCA Protein Assay Kit) of Biyuntian Biotechnology Co., Ltd. as a detection tool, and the BCA protein concentration determination kit (Enhanced) is developed based on the BCA method, one of the two most commonly used protein concentration detection methods in the world, and achieves high stability, high sensitivity and high compatibility of protein concentration determination results. In this experiment, bovine serum albumin was used as a standard, and a standard curve and a linear equation (see Fig.18 ), quantitatively analyze the expression of secreted HSA in each batch of fermentation broth in the fermenter; the specific method is to sample the fermentation broth in the fermenter at different time points during the induction expression phase, centrifuge the fermentation samples (using 5000g×20min), discard the bacteria, and retain the supernatant; after the fermentation of this batch is completed, the retained fermentation supernatant samples are subjected to SDS-PAGE electrophoresis, and then stained with Coomassie Brilliant Blue to observe the electrophoresis results, see Fig.15 , Fig.16 and Fig.17 On the other hand, the retained fermentation supernatant samples were appropriately diluted, loaded with a 96-well plate and a colorimetric agent, and the samples were tested according to the instructions of the BCA protein concentration assay kit (enhanced), and the expression levels of human serum albumin at different time points during the fermentation process were calculated, and some of the results are shown in Tables 4 and 5. In addition, the expression levels of recombinant HSA of 9 batches of fermentation experiments are shown in Table 6.
[0345] Table 4 Target protein concentration in the supernatant of the engineered strain C7 at different time points in the 50L fermenter fermentation test
[0346]
[0347] Table 5 Target protein concentrations in the supernatant of the engineered strain C1 at different time points in the 50 L fermenter fermentation test
[0348]
[0349] Table 6 Experimental results of multi-batch production of recombinant human serum albumin using high-density fermentation technology
[0350]
[0351] In Table 6, C represents CBS7435 engineered bacteria; G represents GS115 engineered bacteria
[0352] Step S300 is specifically as follows:
[0353] S310, taking out the fermentation liquid;
[0354] S320, centrifuging the fermentation broth;
[0355] S330, supernatant membrane filtration;
[0356] S340, heat treatment;
[0357] S350, secondary membrane filtration;
[0358] S360, chromatography;
[0359] The step S310 specifically involves taking out the fermentation liquid from the fermentation tank after the fermentation in step S2.
[0360] The step S320 specifically includes centrifuging the fermentation liquid taken out from step S310 at 9000 rpm and controlling the temperature to be below 30° C.
[0361] The step S330 specifically involves subjecting the fermentation supernatant obtained after centrifugation in step S320 to hollow fiber membrane filtration to obtain filtered fermentation supernatant.
[0362] The step S340 specifically comprises adding sodium octanoate to the filtered fermentation supernatant obtained in step S330 to make the final concentration of sodium octanoate 5 mmol / L, adjusting the pH value to 5.8-7.0, and heating at 68° C. for 30 min; rapidly cooling, and then adjusting the pH value to 4.5 with acetic acid to obtain the heat-treated fermentation supernatant.
[0363] The step S350 specifically involves subjecting the heat-treated fermentation supernatant obtained in step S340 to further hollow fiber membrane filtration to obtain the fermentation supernatant to be purified.
[0364] The step S360 specifically involves performing chromatography on the fermentation supernatant to be purified obtained in S350 to obtain purified recombinant human serum albumin.
[0365] The column chromatography selection
[0366] TH-MC composite mode SP cation exchange column chromatography and hydroxyapatite type II (HAPⅡ) chromatography and DEAE anion exchange column chromatography three-step column chromatography;
[0367] or
[0368] TH-MC composite mode SP cation exchange column chromatography, hydroxyapatite type II (HAPⅡ) column chromatography and TA-phenyl-HIC hydrophobic column chromatography, etc. three-step column chromatography.
[0369] The purified recombinant human serum albumin sample was subjected to gel electrophoresis, and the gel electrophoresis showed a single band, such as Fig.19 The purity of the recombinant human serum albumin sample was 99.03% by HPLC liquid phase detection. Fig. 20 .
[0370] The purified recombinant human serum albumin sample (No. P7901-PH-E) and the rHSA national standard (purchased from the China Food and Drug Inspection Institute) were subjected to a preliminary study on the mass spectrometry molecular weight characterization method. Mass spectrometry-SEC and RP elution conditions were used for comparative study under non-reducing and reducing conditions. The results showed that under the above conditions, the total ion chromatogram (TIC) and TIC chromatogram showed a single peak, and the peak time and peak shape were highly consistent (see Fig.21 and Fig. 22 ). Further experiments were conducted using electrospray mass spectrometry to determine the molecular weight. The results showed that the recombinant human serum albumin sample (No. P7901-PH-E) provided by us and the rHSA national standard product had reduced molecular weight mass spectrometry results of 66477.0 and 66487.5Da, respectively, which were highly consistent with the theoretical molecular weight of HSA of 66472Da. Fig.23 .
[0371] The fermentation process of human serum albumin in this embodiment has the following beneficial effects:
[0372] 1) Through the optimization design of the full sequence of the target gene at the molecular level, the target gene with the best expression in Pichia pastoris is obtained; 2) At the cellular level, by introducing the latest Pichia pastoris expression system host bacteria CBS7435 in the world, it is used for the gene expression of human serum albumin; the G418 resistance gene is used to screen Pichia pastoris transformants containing high-copy number exogenous genes, and is used to construct Pichia pastoris engineering bacteria with high-level expression of recombinant human serum albumin; 3) At the engineering level, by exploring the optimization scheme of fermentation culture process and reactor process control, the expression level of the target protein is further improved; 4) In terms of purification process, the serious defects existing in the existing purification process of recombinant human serum albumin are analyzed and absorbed, and the latest purification media, purification technology, purification methods, etc. at home and abroad are introduced. Only pretreatments such as solid-liquid separation of fermentation broth, heat treatment and ultrafiltration concentration are used, and the entire purification process is completed by three-step column chromatography. The purity of recombinant human serum albumin reaches more than 99%, and the recovery rate of the entire purification process reaches more than 60%.
[0373] The above-described embodiments only express a certain implementation mode of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the patent scope of the present invention. It should be pointed out that, for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims.
[0374] The present invention relates to the sequence:
[0375] SEQ ID NO:1
[0376]
[0377] SEQ ID NO:2
[0378]
[0379] SEQ ID NO:3
[0380] DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRH PYFYAPELLFFAKRYKAAFTECCQAADKAACLLPCLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAE VENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRPDYSVVLLLRLAKTYETTLEKCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
[0381] SEQ ID NO:4
[0382] GAATTCAAAAGA
[0383] SEQ ID NO:5
[0384] TAATAGGCGGGCCGC.
Claims
1. A fermentation process for human serum albumin, characterized in that: The steps include: S210, preparing culture medium; S220, electrode calibration; S230, feeding; S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin; S250, fermentation; S260, place the can.
2. The fermentation process of human serum albumin according to claim 1, characterized in that: The novel host bacteria for highly expressing human serum albumin in step S240 is Pichia pastoris HSA-C16, which is deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with a deposit number of CGMCC No. 30175 and a deposit date of March 28, 2024.
3. The fermentation process of human serum albumin according to claim 1, characterized in that: The culture medium of step S210 includes the following components: H3PO4, CaSO4·2H2O, K2SO4, MgSO4·7H2O, KOH, biotin, ammonia water, 98% glycerol or 100% methanol, and a defoaming agent.
4. The fermentation process of human serum albumin according to claim 3, characterized in that: The content of H3PO4 is 26.7 ml / L, the content of CaSO4·2H2O is 0.47 g / L, the content of K2SO4 is 9.1 g / L, the content of MgSO4·7H2O is 7.5 g / L, the content of KOH is 4.13 g / L, the content of 98% glycerol is 40 g / L, the concentration of methanol in the fermentation liquid in the tank is controlled at 0.2-0.9%, and the content of defoaming agent is 0.5 ml / L.
5. The fermentation process of human serum albumin according to claim 1, characterized in that: The electrode calibration in step S200 specifically includes calibrating the pH electrode and the dissolved oxygen electrode of the fermentation tank.
6. The fermentation process of human serum albumin according to claim 1, characterized in that: The step S230 of feeding specifically includes feeding the culture medium mixture prepared in step S210, and then extinguishing the fire at high temperature and cooling it for standby use.
7. The fermentation process of human serum albumin according to claim 2, characterized in that: The novel host bacteria for highly expressing human serum albumin is an engineered bacterium for expressing gene recombinant HSA obtained by introducing a recombinant expression vector into Pichia pastoris CBS7435 strain. The nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO:
1.
8. The fermentation process of human serum albumin according to claim 7, characterized in that: The recombinant expression vector comprises: (1) A 5' regulatory region derived from Pichia pastoris, comprising a promoter element, wherein the 5' regulatory region is selected from the alcohol oxidase AOX1 gene, the dihydroxyacetone synthase DAS1 gene or the histidinol dehydrogenase HIS4 gene derived from Pichia pastoris, and the 3' end of the regulatory region is connected to the sequence of (2) below; (2) An optimized gene encoding human serum albumin, wherein the nucleotide sequence contained therein is as shown in SEQ ID NO:2, and the amino acid sequence contained therein is as shown in SEQ ID NO:3; (3) A 3' terminator sequence derived from methanolic yeast, wherein the 3' terminator sequence is selected from the 3' terminator sequence of AOX1 gene, AOX2 gene or His4 gene derived from Pichia pastoris.
9. A fermentation process for human serum albumin according to claim 8, characterized in that: Also includes At least one marker gene that can be selected in E. coli; A DNA fragment with a replication origin capable of replicating in an E. coli host bacterium; The invention also comprises at least two marker genes which can be selected in yeast.
10. The fermentation process of human serum albumin according to claim 7, characterized in that: The recombinant expression vector is a linearized vector of any one of pPIC9, pPIC3, pPICZαABC, pPIC3.5K, pHIL-S1, pHIL-D2, pA0804, pA0815, pGAPZαABC, pPIC6αABC, and pPIC9K after being digested with restriction endonuclease SacI or BglⅡ.
11. A fermentation process for human serum albumin according to claim 10, characterized in that: The recombinant expression vector is a linearized vector obtained by digesting HSA-pPIC9K with restriction endonuclease SacI or BglII, and contains at least one copy of an optimized gene encoding human serum albumin that is optimally designed.
12. The fermentation process of human serum albumin according to claim 10, characterized in that: In the optimized gene encoding human serum albumin, the preferred codons of the Pichia pastoris alcohol oxidase (AOX1) gene are selected and the preferred codons of the gene are controlled to account for 90% of the total number of the optimized gene codons.
13. The fermentation process of human serum albumin according to claim 10, characterized in that: In the optimized gene encoding human serum albumin, three restriction endonuclease sites, namely SalI, Hind III and Xba I, are sequentially inserted from 5' to 3' inside the optimized gene, so that the optimized gene is relatively evenly divided into four large fragments.
14. The fermentation process of human serum albumin according to claim 10, characterized in that: In the optimized gene encoding human serum albumin, continuous GC pairing is reduced, and AT pairing preferred by Pichia pastoris is increased, so that the GC content inside the optimized gene is adjusted to 45-50%.
15. The fermentation process of human serum albumin according to claim 10, characterized in that: The optimized gene encoding human serum albumin also includes an expression reading frame of The restriction endonuclease BamHI site at the 5' end was inserted into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxyoligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e. AXXATG), and then the yeast a-mating child leader peptide (consisting of 85 amino acids) sequence from Saccharomyces cerevisiae, and then the HSA mature gene was inserted between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector; The coding sequence AAAAGA of two dibasic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene, and the specific sequence is SEQ ID NO: 4; the double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene, and the specific sequence is SEQ ID NO:
5.
16. The fermentation process of human serum albumin according to claim 10, characterized in that: The fermentation in step S250 includes a basic culture stage, a transition culture stage and an induced expression stage.
17. A fermentation process for human serum albumin according to claim 16, characterized in that: The basic training stage is specifically: At the beginning of the fermentation of engineered bacteria, the SCADA process control software was started to record data, fermentation time and batch number, and the map record was turned on; from the time the inoculated bacteria were put into the fermentation tank, the relevant fermentation data were recorded regularly every 4 hours; the control parameters were set as follows: pH was controlled at 5.5±0.1 with ammonia water, and the temperature was controlled at 28±1℃; DO value was controlled above 30, air flow was 2vvm, and tank pressure was controlled at 0.03~0.04Mpa; after DO rebounded, it entered the transition culture phase; sampling was taken to detect OD during the rebound 600 It should be around 50.
18. The fermentation process of human serum albumin according to claim 17, characterized in that: The transitional culture stage is specifically After DO rebounds during the transitional culture stage, 50% glycerol is immediately fed, and 12 ml / L of PTM1 solution containing biotin is added to the 50% glycerol. At the same time, the stirring is adjusted to the maximum speed specified by the fermenter, the air flow is adjusted to 2vvm, and the tank pressure is adjusted to 0.04-0.08Mpa. Under this condition, the feeding rate controls the DO value at 30±10; DO-Spike is performed at least once every hour to ensure that the DO-Spike response time is less than 60 seconds; the feeding cycle is about 4-5 hours; when glycerol is fed, the pH setting value is adjusted on average every hour so that the pH is the induced pH value of 5.7 required by the project after the glycerol feeding is completed; at the end of the transitional culture, OD 600 ≈100.
19. A fermentation process for human serum albumin according to claim 18, characterized in that: The induction expression stage is specifically: After the addition of glycerol stops, after the dissolved oxygen DO rebound is observed, 4g / L of methanol is added and 12ml / L of PTM1 is added to the methanol; after the methanol to be added is consumed (DO rebound), methanol is started to be added in a DO-Spike manner, and the DO-Spike response time is less than 60 seconds, and the DO value is controlled at 10-30; at the same time as the methanol is started, the temperature is adjusted to 24°C; the pH is controlled at the project specified pH 5.7; and DO-Spike is performed every 12 hours, and the response time and other fermentation data are recorded; sampling is performed every 12 hours, the pH and the wet weight of the engineered bacteria are tested, centrifuged, 100μl of the supernatant is added to the electrophoresis buffer, boiled at 100°C for 5 minutes, and stored at -20°C; the remaining supernatant is stored in a refrigerator at 2-8°C for detection or electrophoresis analysis; the samples are marked when sampling; during the induction expression stage, the methanol concentration in the fermentation liquid in the tank is maintained between 0.2-0.9%.
Citation Information
Patent Citations
Transformation of yeasts of the genus pichia
US4879231A
Genetically engineered micro-organism expressing human serum albumin and preparation method and application thereof
CN109957521A
Human serum albumin optimized gene suitable for being expressed in pichia pastoris and method for expressing human serum albumin optimized gene in pichia pastoris
CN118389529A
Chemical synthesis, expression and recombinant protein production for human serum albumin reformed gene
CN1266100A
Methylotrophic yeast strain pichia pastoris yst-HSA-PDI1, producing recombinant human serum albumin
RU2733423C1
